Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

The Neuroimmune Axis in the Tumor Microenvironment.

Shurin MR, Shurin GV, Zlotnikov SB, Bunimovich YL.

J Immunol. 2020 Jan 15;204(2):280-285. doi: 10.4049/jimmunol.1900828. Review.

PMID:
31907270
2.

Racial Differences in S100b Levels in Persons with Schizophrenia.

Gannon JM, Kelly DL, Besch A, Thakur T, Khurana N, Shurin MR, Shurin GV, Brar JS, Cihakova D, Talor MV, Chengappa KNR.

Psychiatr Q. 2019 Nov 30. doi: 10.1007/s11126-019-09687-4. [Epub ahead of print]

PMID:
31786729
3.

Immunomodulation by Schwann cells in disease.

Zhang SH, Shurin GV, Khosravi H, Kazi R, Kruglov O, Shurin MR, Bunimovich YL.

Cancer Immunol Immunother. 2019 Nov 1. doi: 10.1007/s00262-019-02424-7. [Epub ahead of print] Review.

PMID:
31676924
4.

Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.

Gutkin DW, Shurin MR, El Azher MA, Shurin GV, Velikokhatnaya L, Prosser D, Shin N, Modugno F, Stemmer P, Elishaev E, Lokshin A.

Cancer Biomark. 2019;26(4):471-479. doi: 10.3233/CBM-190528.

5.

Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth.

Shurin GV, Kruglov O, Ding F, Lin Y, Hao X, Keskinov AA, You Z, Lokshin AE, LaFramboise WA, Falo LD Jr, Shurin MR, Bunimovich YL.

Cancer Res. 2019 May 15;79(10):2736-2747. doi: 10.1158/0008-5472.CAN-18-3872. Epub 2019 Mar 26.

PMID:
30914431
6.

Schwann cells shape the neuro-immune environs and control cancer progression.

Martyn GV, Shurin GV, Keskinov AA, Bunimovich YL, Shurin MR.

Cancer Immunol Immunother. 2019 Nov;68(11):1819-1829. doi: 10.1007/s00262-018-02296-3. Epub 2019 Jan 3. Review.

PMID:
30607548
7.

Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.

Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, Dinarello CA, Voronov E, Apte RN.

Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369. doi: 10.1073/pnas.1812266115. Epub 2018 Dec 13.

8.

Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups.

Burkert SC, Shurin GV, White DL, He X, Kapralov AA, Kagan VE, Shurin MR, Star A.

Nanoscale. 2018 Sep 27;10(37):17990-18000. doi: 10.1039/c8nr04437f.

9.

Schwann Cells Augment Cell Spreading and Metastasis of Lung Cancer.

Zhou Y, Shurin GV, Zhong H, Bunimovich YL, Han B, Shurin MR.

Cancer Res. 2018 Oct 15;78(20):5927-5939. doi: 10.1158/0008-5472.CAN-18-1702. Epub 2018 Aug 22.

10.

Nanoelectronic Discrimination of Nonmalignant and Malignant Cells Using Nanotube Field-Effect Transistors.

Silva GO, Michael ZP, Bian L, Shurin GV, Mulato M, Shurin MR, Star A.

ACS Sens. 2017 Aug 25;2(8):1128-1132. doi: 10.1021/acssensors.7b00383. Epub 2017 Aug 9.

11.

Fibrillar vs crystalline nanocellulose pulmonary epithelial cell responses: Cytotoxicity or inflammation?

Menas AL, Yanamala N, Farcas MT, Russo M, Friend S, Fournier PM, Star A, Iavicoli I, Shurin GV, Vogel UB, Fadeel B, Beezhold D, Kisin ER, Shvedova AA.

Chemosphere. 2017 Mar;171:671-680. doi: 10.1016/j.chemosphere.2016.12.105. Epub 2016 Dec 24.

12.

Schwann cells: a new player in the tumor microenvironment.

Bunimovich YL, Keskinov AA, Shurin GV, Shurin MR.

Cancer Immunol Immunother. 2017 Aug;66(8):959-968. doi: 10.1007/s00262-016-1929-z. Epub 2016 Nov 24. Review.

13.

In Vitro Toxicity Evaluation of Lignin-(Un)coated Cellulose Based Nanomaterials on Human A549 and THP-1 Cells.

Yanamala N, Kisin ER, Menas AL, Farcas MT, Khaliullin TO, Vogel UB, Shurin GV, Schwegler-Berry D, Fournier PM, Star A, Shvedova AA.

Biomacromolecules. 2016 Nov 14;17(11):3464-3473. Epub 2016 Oct 21.

PMID:
27709894
14.

BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo.

Shurin MR, Ma Y, Keskinov AA, Zhao R, Lokshin A, Agassandian M, Shurin GV.

Cancer Res. 2016 Sep 1;76(17):4959-69. doi: 10.1158/0008-5472.CAN-15-2668. Epub 2016 Jun 30.

15.

Impact of the Sensory Neurons on Melanoma Growth In Vivo.

Keskinov AA, Tapias V, Watkins SC, Ma Y, Shurin MR, Shurin GV.

PLoS One. 2016 May 26;11(5):e0156095. doi: 10.1371/journal.pone.0156095. eCollection 2016.

16.

Tumor-derived factors modulating dendritic cell function.

Zong J, Keskinov AA, Shurin GV, Shurin MR.

Cancer Immunol Immunother. 2016 Jul;65(7):821-33. doi: 10.1007/s00262-016-1820-y. Epub 2016 Mar 16. Review.

PMID:
26984847
17.

Payload drug vs. nanocarrier biodegradation by myeloperoxidase- and peroxynitrite-mediated oxidations: pharmacokinetic implications.

Seo W, Kapralov AA, Shurin GV, Shurin MR, Kagan VE, Star A.

Nanoscale. 2015 May 21;7(19):8689-94. doi: 10.1039/c5nr00251f.

18.

MDSC and TGFβ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes.

Shvedova AA, Kisin ER, Yanamala N, Tkach AV, Gutkin DW, Star A, Shurin GV, Kagan VE, Shurin MR.

Cancer Res. 2015 Apr 15;75(8):1615-23. doi: 10.1158/0008-5472.CAN-14-2376. Epub 2015 Mar 5.

19.

Nano-gold corking and enzymatic uncorking of carbon nanotube cups.

Zhao Y, Burkert SC, Tang Y, Sorescu DC, Kapralov AA, Shurin GV, Shurin MR, Kagan VE, Star A.

J Am Chem Soc. 2015 Jan 21;137(2):675-84. doi: 10.1021/ja511843w. Epub 2015 Jan 7.

20.

C-reactive protein and lung diseases.

Agassandian M, Shurin GV, Ma Y, Shurin MR.

Int J Biochem Cell Biol. 2014 Aug;53:77-88. doi: 10.1016/j.biocel.2014.05.016. Epub 2014 May 19. Review.

PMID:
24853773
21.

Graphene oxide attenuates Th2-type immune responses, but augments airway remodeling and hyperresponsiveness in a murine model of asthma.

Shurin MR, Yanamala N, Kisin ER, Tkach AV, Shurin GV, Murray AR, Leonard HD, Reynolds JS, Gutkin DW, Star A, Fadeel B, Savolainen K, Kagan VE, Shvedova AA.

ACS Nano. 2014 Jun 24;8(6):5585-99. doi: 10.1021/nn406454u. Epub 2014 May 23.

22.

Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.

Zhong H, Gutkin DW, Han B, Ma Y, Keskinov AA, Shurin MR, Shurin GV.

Int J Cancer. 2014 Jun 1;134(11):2633-45. doi: 10.1002/ijc.28590. Epub 2014 Jan 20.

23.

Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.

Landreneau JP, Shurin MR, Agassandian MV, Keskinov AA, Ma Y, Shurin GV.

Cancer Microenviron. 2015 Aug;8(2):57-64. doi: 10.1007/s12307-013-0141-3. Epub 2013 Nov 29.

24.

Early growth response-2 signaling mediates immunomodulatory effects of human multipotential stromal cells.

Barbeau DJ, La KT, Kim DS, Kerpedjieva SS, Shurin GV, Tamama K.

Stem Cells Dev. 2014 Jan 15;23(2):155-66. doi: 10.1089/scd.2013.0194. Epub 2013 Oct 5.

25.

Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Shurin GV, Ma Y, Shurin MR.

Cancer Microenviron. 2013 Aug;6(2):159-67. doi: 10.1007/s12307-013-0133-3. Epub 2013 Jun 9.

26.

The role of TLR4 in the paclitaxel effects on neuronal growth in vitro.

Ustinova EE, Shurin GV, Gutkin DW, Shurin MR.

PLoS One. 2013;8(2):e56886. doi: 10.1371/journal.pone.0056886. Epub 2013 Feb 18.

27.

Dendritic cells in the cancer microenvironment.

Ma Y, Shurin GV, Peiyuan Z, Shurin MR.

J Cancer. 2013;4(1):36-44. doi: 10.7150/jca.5046. Epub 2012 Dec 15.

28.

Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.

Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR, Umansky V.

J Immunol. 2013 Mar 1;190(5):2464-71. doi: 10.4049/jimmunol.1202781. Epub 2013 Jan 28.

29.

Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells.

Shvedova AA, Tkach AV, Kisin ER, Khaliullin T, Stanley S, Gutkin DW, Star A, Chen Y, Shurin GV, Kagan VE, Shurin MR.

Small. 2013 May 27;9(9-10):1691-5. doi: 10.1002/smll.201201470. Epub 2012 Sep 20.

30.

Graphene oxide, but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells.

Tkach AV, Yanamala N, Stanley S, Shurin MR, Shurin GV, Kisin ER, Murray AR, Pareso S, Khaliullin T, Kotchey GP, Castranova V, Mathur S, Fadeel B, Star A, Kagan VE, Shvedova AA.

Small. 2013 May 27;9(9-10):1686-90. doi: 10.1002/smll.201201546. Epub 2012 Aug 13.

31.

Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice.

Sevko A, Kremer V, Falk C, Umansky L, Shurin MR, Shurin GV, Umansky V.

J Immunotoxicol. 2012 Jul-Sep;9(3):275-81. doi: 10.3109/1547691X.2012.655343. Epub 2012 Mar 27.

PMID:
22449053
32.

Tumor associated regulatory dendritic cells.

Ma Y, Shurin GV, Gutkin DW, Shurin MR.

Semin Cancer Biol. 2012 Aug;22(4):298-306. doi: 10.1016/j.semcancer.2012.02.010. Epub 2012 Mar 6. Review.

33.

ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents.

Shurin MR, Naiditch H, Gutkin DW, Umansky V, Shurin GV.

Curr Med Chem. 2012;19(12):1792-803. Review.

PMID:
22414087
34.

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.

Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR.

J Immunotoxicol. 2012 Jul-Sep;9(3):292-300. doi: 10.3109/1547691X.2011.642418. Epub 2012 Jan 28.

35.

Regulatory dendritic cells in the tumor immunoenvironment.

Shurin GV, Ouellette CE, Shurin MR.

Cancer Immunol Immunother. 2012 Feb;61(2):223-230. doi: 10.1007/s00262-011-1138-8. Epub 2011 Nov 8. Review.

36.

Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.

Naiditch H, Shurin MR, Shurin GV.

Immunol Res. 2011 Aug;50(2-3):276-85. doi: 10.1007/s12026-011-8213-2.

PMID:
21717082
37.

Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure.

Tkach AV, Shurin GV, Shurin MR, Kisin ER, Murray AR, Young SH, Star A, Fadeel B, Kagan VE, Shvedova AA.

ACS Nano. 2011 Jul 26;5(7):5755-62. doi: 10.1021/nn2014479. Epub 2011 Jun 15.

38.

Regulatory dendritic cells: new targets for cancer immunotherapy.

Shurin MR, Naiditch H, Zhong H, Shurin GV.

Cancer Biol Ther. 2011 Jun 1;11(11):988-92. Epub 2011 Jun 1. No abstract available.

PMID:
21474998
39.

Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells.

Kaneno R, Shurin GV, Kaneno FM, Naiditch H, Luo J, Shurin MR.

Cell Oncol (Dordr). 2011 Apr;34(2):97-106. doi: 10.1007/s13402-010-0005-5. Epub 2011 Jan 20.

PMID:
21290210
40.

Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.

Song EY, Shurin MR, Tourkova IL, Gutkin DW, Shurin GV.

Cancer Res. 2010 Jun 1;70(11):4394-401. doi: 10.1158/0008-5472.CAN-10-0427. Epub 2010 May 11.

41.

Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations.

Kaneno R, Shurin GV, Tourkova IL, Shurin MR.

J Transl Med. 2009 Jul 10;7:58. doi: 10.1186/1479-5876-7-58.

42.

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.

Shurin GV, Tourkova IL, Kaneno R, Shurin MR.

J Immunol. 2009 Jul 1;183(1):137-44. doi: 10.4049/jimmunol.0900734. Epub 2009 Jun 17.

43.

Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer.

Shurin MR, Potapovich AI, Tyurina YY, Tourkova IL, Shurin GV, Kagan VE.

Cancer Res. 2009 Mar 15;69(6):2487-96. doi: 10.1158/0008-5472.CAN-08-2611. Epub 2009 Mar 10.

44.

Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells.

Tourkova IL, Shurin GV, Ferrone S, Shurin MR.

Cancer Immunol Immunother. 2009 Apr;58(4):567-74. doi: 10.1007/s00262-008-0579-1. Epub 2008 Aug 28.

45.

Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays.

Kirillova GP, Hrutkay RJ, Shurin MR, Shurin GV, Tourkova IL, Vanyukov MM.

J Neurosci Methods. 2008 Sep 30;174(2):272-80. doi: 10.1016/j.jneumeth.2008.07.018. Epub 2008 Aug 5.

46.

Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Shurin GV, Tourkova IL, Shurin MR.

J Immunother. 2008 Jun;31(5):491-9. doi: 10.1097/CJI.0b013e318176fae4.

47.

Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.

Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR, Shurin GV.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5455-62.

48.

Gangliosides as immunomodulators.

Potapenko M, Shurin GV, de León J.

Adv Exp Med Biol. 2007;601:195-203. Review.

PMID:
17713006
49.

Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA.

Aalamian-Matheis M, Chatta GS, Shurin MR, Huland E, Huland H, Shurin GV.

Adv Exp Med Biol. 2007;601:173-82.

PMID:
17713004
50.

Dynamic alteration of soluble serum biomarkers in healthy aging.

Shurin GV, Yurkovetsky ZR, Chatta GS, Tourkova IL, Shurin MR, Lokshin AE.

Cytokine. 2007 Aug;39(2):123-9. Epub 2007 Aug 8.

PMID:
17689975

Supplemental Content

Loading ...
Support Center